Mark B. Roth

Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA.

Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham.

Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Acylin Therapeutics, Inc. develops drugs for cancer. The company was founded by Philip A. Cole, Peter S. DiStefano, Ronen Marmorstein, Suresh K. Jain and Roydon Price in 2009 and is headquartered in Seattle, WA.

Jagen Pty Ltd. provides business consulting services. The company was founded by Doron Ben-Meir and Moshe Shahaf and is headquartered in Kew, Australia.

ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.

Celdara Medical LLC engages in development of early-stage medical inventions and discoveries. It builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical was founded in 2008 by Jake Reder and Michael W. Fanger and is headquartered in Lebanon, NH.

W Fund Management LLC (W Fund) is a venture capital firm founded in 2012 by Mr. Hamburg Robert. The firm is headquartered in Seattle, Washington.

Just Biotherapeutics, Inc. operates as biotechnology firm. Its products include biosimilars and novel and repositioned biologics. The firm also offers molecular design, process and product platform and manufacturing and plant design services. The company was founded by James N. Thomas, Victor P. Fung, Dean K. Pettit, and Yining Zhao in 2014 and is headquartered in Seattle, WA.

OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA.

Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY.

Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY.

eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA.

Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014.

Verband Beratender Ingenieure VBI is a consulting and engineering association based in Germany.

Proniras Corp. operates as a bio technology company. The company is headquartered in Seattle, WA.

Hibercell, Inc. specializes on tumor dormancy detection and therapeutics. It provides treatment for primary tumors, metastatic cancer. The company was founded by Alan Rigby, Julio Aguirre-Ghiso, and Ari Nowacek and is headquartered in New York, NY.

JBR Pharma, Inc. operates as a virtual pharmaceutical company. The company is headquartered in Plymouth Meeting, PA.

Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.

Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.

Skylark Bio, Inc. operates as a biotechnology company. The company is based in Cambridge, MA.

hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then.

SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation.

TFC Therapeutics, Inc. is a biotech company based in New York, NY. TFC Therapeutics is developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. The company is blending early-stage research with innovative platform design to develop next-generation treatments to eliminate the most resilient cancers and put an end to their recurrence before it begins. The company was founded in 2022 and Jennifer Power has been the CEO of the company since 2023.